Pharmaceutical News

RSS

Fertility medications not linked with increased risk of CVD later in life

Women who gave birth following fertility treatment had no long-term increased risk of death or major cardiovascular events compared to women who gave birth without fertility therapy, according to new research by the Institute for Clinical Evaluative Sciences (ICES) and Women's College Hospital.

1 Aug 2013

Baxter, JW Holdings sign distribution, license agreement for omega 3 parenteral nutrition products

Baxter International Inc. and JW Holdings today announced that they have entered into an exclusive distribution and license agreement for parenteral nutritional products containing a novel formulation of omega 3 lipids.

From Baxter International Inc. 31 Jul 2013

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca and FibroGen today announced that they have entered into a strategic collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease and end-stage renal disease.

31 Jul 2013

Combination of tPA with infusion of antiplatelet drug dissolves blood clots safely

The combination of the clot-busting drug tPA with an infusion of the antiplatelet drug eptifibatide dissolves blood clots safely and more quickly than tPA alone, a study led by University of Cincinnati (UC) researchers has found.

31 Jul 2013

Antibiotic prescribing rates can be reduced using internet-based training for clinicians

Antibiotic prescribing rates for acute respiratory tract infections could be significantly lowered using internet-based training for clinicians, new research has shown.

31 Jul 2013

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

With oral anticoagulant rivaroxaban set to be subsidised under the Pharmaceutical Benefits Scheme (PBS) for preventing stroke, NPS MedicineWise is urging people to talk to their doctor before stopping or making any changes to their anticoagulant medicines.

30 Jul 2013

METH use can make person more susceptible to fungal lung infection

Methamphetamine use can make a person more susceptible to the lung infection cryptococcosis, according to a study published in mBio-, the online open-access journal of the American Society for Microbiology.

30 Jul 2013

FDA grants orphan-drug designation to Convergence's CNV1014802 for treatment of TN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, is pleased to announce that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation by the US Food and Drug Administration for the treatment of trigeminal neuralgia.

30 Jul 2013

FDA accepts NDA for MNK-795 oral formulation

Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.

30 Jul 2013

Statins: A class of cholesterol-lowering drugs may help treat Rett Syndrome

Statins, a class of cholesterol-lowering drugs found in millions of medicine cabinets, may help treat Rett Syndrome, according to a study published today in Nature Genetics. The Rett Syndrome Research Trust (RSRT) funded this work with generous support from the Rett Syndrome Research Trust UK and Rett Syndrome Research & Treatment Foundation.

30 Jul 2013

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

Anacor Pharmaceuticals announced today that on July 26, 2013 it submitted its New Drug Application to the U.S. Food and Drug Administration for tavaborole, its drug candidate for the topical treatment of onychomycosis. Onychomycosis is a fungal infection of the nail and nail bed that affects approximately 35 million people in the United States.

30 Jul 2013

CHMP gives positive opinion for approval of once-daily QVA149 for treatment of COPD

Sosei Group Corporation confirms the information released by Novartis that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler®, as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

29 Jul 2013

Technique for developing more targeted drugs using molecular "robots"

Many drugs such as agents for cancer or autoimmune diseases have nasty side effects because while they kill disease-causing cells, they also affect healthy cells. Now a new study has demonstrated a technique for developing more targeted drugs, by using molecular "robots" to hone in on more specific populations of cells.

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

26 Jul 2013

Compliance leaders give insight and thoughts in new ebook

Regulatory non compliance costs the pharma industry billions in fines, audits and much more each year. To avoid these fines and bad reputation pharma companies rely heavily on their compliance teams, who provide oversight from R&D to the very end of a product cycle.

26 Jul 2013

FDA acknowledges receipt of NDA resubmission of dapagliflozin drug for treatment of type 2 diabetes

AstraZeneca (NYSE: AZN) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission for investigational drug dapagliflozin for the treatment of adults with type 2 diabetes.

26 Jul 2013

Rapamycin extends mice lifespan but has limited effects on aging

The body's repair mechanisms begin to fail with increasing age. As a result, signs of wear and tear appear and the risk for many diseases, including Alzheimer's disease, diabetes, cardiovascular disorders and cancer, increases.

26 Jul 2013

New research provides insight into mechanisms, action of Radix Achyranthis Bidentatae

A research team from the School of Basic Medical Sciences, Beijing University of Chinese Medicine reports that Radix Achyranthis Bidentatae can inhibit advanced glycation end product formation, reduce their levels in the frontal cortex, and improve learning and memory capabilities in ovariectomized rats.

26 Jul 2013

Epigenetic changes induced by ADO therapy prevent epilepsy progression

Epilepsy is characterized by recurrent seizures that present in many different ways. In some cases epileptic patients exhibit a progressive increase in both frequency and severity of seizures. Epigenetic changes such as DNA methylation have recently been implied as an underlying cause of several neurologic disorders, including epilepsy.

26 Jul 2013

Pharmaceutical News

Fertility medications not linked with increased risk of CVD later in life

Baxter, JW Holdings sign distribution, license agreement for omega 3 parenteral nutrition products

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

Combination of tPA with infusion of antiplatelet drug dissolves blood clots safely

Antibiotic prescribing rates can be reduced using internet-based training for clinicians

NPS MedicineWise finds little or no clinical benefit in switching to rivaroxaban for stroke prevention

METH use can make person more susceptible to fungal lung infection

FDA grants orphan-drug designation to Convergence's CNV1014802 for treatment of TN

FDA accepts NDA for MNK-795 oral formulation

Statins: A class of cholesterol-lowering drugs may help treat Rett Syndrome

Anacor Pharmaceuticals submits tavaborole NDA to FDA for treatment of onychomycosis

CHMP gives positive opinion for approval of once-daily QVA149 for treatment of COPD

Technique for developing more targeted drugs using molecular "robots"

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Compliance leaders give insight and thoughts in new ebook

FDA acknowledges receipt of NDA resubmission of dapagliflozin drug for treatment of type 2 diabetes

Rapamycin extends mice lifespan but has limited effects on aging

New research provides insight into mechanisms, action of Radix Achyranthis Bidentatae

Epigenetic changes induced by ADO therapy prevent epilepsy progression

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News